Oral Contraceptive Interaction Study for GW273225

Bipolar Disorder Clinical Trial

Official title:

An Open, Repeat Dose Study to Investigate the Effect of Co-administration of the Combined Oral Contraceptive Pill (COC) and GW273225 on the Pharmacokinetics of the COC and to Investigate the Effects of the COC on the Pharmacokinetics of GW273225 in Healthy Female Subjects

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00483535
• Other study ID #: NEC107110
• Status: Terminated
• Phase: Phase 1
• First received: June 6, 2007
• Last updated: August 5, 2017
• Start date: March 7, 2007
• Est. completion date: November 16, 2007

Study information

• Verified date: August 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

GW273225 is in development for epilepsy and bipolar disorder and can affect women of child bearing potential. A clear understanding of the potential interaction between oral contraceptives and GW273225 is therefore important for clinical investigation of GW273225 in a large number of patients. This study will investigate whether there is any effect of GW273225 upon the components of combined oral contraceptive, and also whether taking oral contraceptives affects the pharmacokinetics (PK) of GW273225.

26 healthy female subjects, aged 18-45 years will take an oral contraceptive (150ug levonorgestrel and 30ug ethinylestrdiol; The study will include a screening period, two cycles on oral contraceptive with GW273225 at 25 mg once per day administered from the start of the second COC cycle for 47 days. There will be a follow-up visit 14-21 days later.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: November 16, 2007
• Est. primary completion date: November 16, 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy female subjects aged between 18 and 45 years, inclusive.

• Body weight >50 kg and Body Mass Index (BMI) within the range 19-29.9 kg/m2 inclusive.

• Female subjects of child bearing potential will be eligible to participate if they are established on a Microgynon 30 or Ovranette for the previous month

• If taking a similar ethinyl oestradiol dose (30 or 35 mcg) combined with a progestogen at fixed dose for 21 days then willing to switch to Microgynon 30

• Subjects will use additional contraception as described in the protocol. One of the methods listed in the protocol is acceptable in conjunction with COC as the method of contraception if there is indisputable data that it is >99% effective, otherwise it should be used with a barrier method (condom or occlusive cap (diaphragm or cervical/vault caps) used with spermicidal foam/gel/film/cream/suppository).

• Subjects must smoke = 10 cigarettes per day.

• No abnormality on relevant clinical examination. A subject with a clinical abnormality may be included only if the Investigator in consultation with the GSK Medical Monitor considers that the abnormality will not introduce additional risk factors and will not interfere with the study procedures.

• No abnormality on relevant clinical chemistry or haematology examination at the pre-study medical examination. Subjects with laboratory parameters outside the reference range for this age group will only be included if the Investigator in consultation with the GSK Medical Monitor considers that such findings will not introduce additional risk factors.

• A 12-lead ECG and vital signs at the pre-study medical examination, which are normal. (including QTc which is <450msec)

• The subject has signed and dated written informed consent prior to admission to the study

• The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.

Exclusion Criteria:

• History or evidence of drug or alcohol abuse within six months of study start.

• Weekly alcohol intake of more than 14 units or an average daily intake of greater than 2 units.

• Female subject pregnant (positive serum human chorionic gonadotrophin (hCG) test at screening) or lactating. HIV, Chronic hepatitis B and C, as evidenced by positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody

• Subject has received prescribed or non-prescribed medication (including vitamins and herbal remedies) within 14 days prior to day 1 which in the opinion of the investigator, could have interfered with the study procedures or compromised safety.

• History of gastro-intestinal, hepatic or renal disease or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.

• History of thrombotic events or presence of significant risk factors for thrombosis.

• Supine Blood Pressure greater than or equal to 140/90.

• Progestogen- releasing IUD contraceptive.

• Participation in a trial with any drug within 84 days before the start of the study.

• Donation of more than 1500 mL blood in the previous 12 months.

• History or presence of any condition contra-indicated to combined oral contraceptive.

• Any subject where the potential side effects of GW273225 could affect their professional occupation, e.g. operating machinery, driving.

• Any subjects who cannot refrain from driving for the duration of administration of GW273225 and for 3 days afterwards.

• History of clinically relevant skin rashes that, in the opinion of the investigator, might interfere with the conduct of the study.

• Subject has current or past history of seizure disorder or brain injury (traumatic or disease-related), or any condition which, in the opinion of the investigator, predisposes to seizure; subject treated with other medications or treatment regimens that lower seizure threshold; subject undergoing abrupt discontinuation of alcohol or sedatives (including benzodiazepines).

Related Conditions & MeSH terms

• Bipolar Disorder

Intervention

Drug:
• GW273225
GW273225 will be available as 25 milligram tablets.
• COC
COC will consist of Microgynon 30 which is available as ethinylestradiol 30 micrograms/levonorgestrel 150 micrograms beige color, sugar-coated tablets.

Locations

Country	Name	City	State
United Kingdom	GSK Investigational Site	Cambridge	Cambridgeshire

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	0-24hrs PK of oral contraceptive components		0-24hrs
Secondary	0-24hrs PK of GW273225 Hormone levels with co-administration of oral contraceptive and GW273225		0-24hrs
Secondary	blood drug levels of GW273225 in the presence or absence of the Combined Oral Contraceptive (COC)		pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post dosing on Day 49 and Day 75
Secondary	blood levels of ethinylestradiol and levonorgestrel of the COC in the presence or absence of GW273225.		pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post dosing on Day 21 and Day 49
Secondary	blood levels of FSH, LH and progesterone		Up to Day 45
Secondary	blood levels of Oestradiol and SBHG		Up to Day 45
Secondary	Electrocardiogram (ECG) recordings		Up to Day 96
Secondary	Adverse events		Up to Day 96
Secondary	Vital signs		Up to Day 96

External Links

•   Results for study 107110 can be found on the GSK Clinical Study Register.